The correlation between fatigue and reactivation of HHV-6 in the patients with multiple myeloma

The correlation between fatigue and reactivation of HHV-6 in the patients with multiple myeloma - The correlation between fatigue and reactivation of HHV-6 in the patients with multiple myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010348

Enrollment

Registered

2013-03-28

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

harvest of saliva, and blood test.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with multiple myeloma 2. To receive chemotherapy 3. ECOG PS = 0-2 4. The hemoglobin level >= a facilities standard value 5. To answer the questions to evaluate the degree of fatigue. 6. Harvest the adequate volume of saliva

Exclusion criteria

Exclusion criteria: 1. Severe phycological disorder 2. Infection of HIV, HTLV=1, HBV, HCV 3. Congenital immunodeficiency 4. Severe complications, such as hypertension, congestive heart failure, coronary artery disease, liver cirrhosis, diabetes mellitus, and respiratory failure.

Design outcomes

Primary

Measure	Time frame
the correlation between fatigue and several markers that represent fatigue, such as the level of HHV6 DNA in saliva, the level of HHV7 DNA in saliva, fatigue factor, fatigue recovery factor, and inflammatory cytokines.	—

Countries

Japan

Contacts

Public ContactKazuhito Suzuki

The Jikei University School of Medicine Devision of Clinical Oncology/ Hematology

kaz-suzuki@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026